The re-evaluation of Elancoban carried out by the Commission showed that the relevant conditions laid down in Directive 70/524/EEC are satisfied. Elancoban should therefore be authorised for 10 years as an additive linked to the person responsible for putting it into circulation and included in Chapter I of the list referred to Article 9t(b) of that Directive.
Recital 5, Commission Regulation (EC) No 1356/2004 of 26 July 2004 concerning the authorisation for…
In forcesince 26 Jul 2004
- celex=31970L0524